These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
974 related articles for article (PubMed ID: 24012040)
1. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
2. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
3. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150 [TBL] [Abstract][Full Text] [Related]
4. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591 [TBL] [Abstract][Full Text] [Related]
5. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139 [TBL] [Abstract][Full Text] [Related]
7. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750 [TBL] [Abstract][Full Text] [Related]
8. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G; J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933 [TBL] [Abstract][Full Text] [Related]
9. Modern treatment strategies in rheumatoid arthritis. Hetland ML Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935 [TBL] [Abstract][Full Text] [Related]
11. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315 [TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR; Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821 [TBL] [Abstract][Full Text] [Related]
16. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM; Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R; Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Symmons DP; Watson KD; Silman AJ; Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [TBL] [Abstract][Full Text] [Related]
19. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J; Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]